MindBio Therapeutics (XCNQ:MBIO) Debt-to-Equity : -0.91 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Debt-to-Equity?

MindBio Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.96 Mil. MindBio Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$3.55 Mil. MindBio Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was C$-4.95 Mil. MindBio Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was -0.91.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MindBio Therapeutics's Debt-to-Equity or its related term are showing as below:

XCNQ:MBIO' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.13 Med: -0.93 Max: -0.89
Current: -0.91

During the past 3 years, the highest Debt-to-Equity Ratio of MindBio Therapeutics was -0.89. The lowest was -1.13. And the median was -0.93.

XCNQ:MBIO's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs XCNQ:MBIO: -0.91

MindBio Therapeutics Debt-to-Equity Historical Data

The historical data trend for MindBio Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Debt-to-Equity Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-Equity

-1.01

-1.06

-0.93

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial					-1.07	-0.93	-0.89	-0.89	-0.91

Competitive Comparison of MindBio Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, MindBio Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Debt-to-Equity falls into.

MindBio Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MindBio Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.922	+	2.512)	/	-4.778
	=	-0.93

MindBio Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.955	+	3.545)	/	-4.95
	=	-0.91

MindBio Therapeutics (XCNQ:MBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MindBio Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.